buspirone has been researched along with Idiopathic Parkinson Disease in 17 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Individuals with PD and clinically significant anxiety were randomized 4:1 to flexible dosage buspirone or placebo for 12 weeks." | 9.34 | A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability. ( Auinger, P; Gil-Díaz, MC; Iourinets, J; Richard, IH; Schneider, RB; Tarolli, CG, 2020) |
| "Individuals with PD and clinically significant anxiety were randomized 4:1 to flexible dosage buspirone or placebo for 12 weeks." | 5.34 | A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability. ( Auinger, P; Gil-Díaz, MC; Iourinets, J; Richard, IH; Schneider, RB; Tarolli, CG, 2020) |
| "Buspirone is a novel anxiolytic whose pharmacological profile differs from that of the benzodiazepines and includes dopaminergic agonist effects." | 2.66 | Buspirone, Parkinson's disease, and the locus ceruleus. ( Bakker, K; Bruno, G; Chase, TN; Gillespie, M; LeWitt, PA; Ludwig, CL; Weinberger, DR, 1986) |
| "Buspirone is a novel anxiolytic chemically unrelated to the benzodiazepines." | 2.66 | Buspirone in the treatment of tardive dyskinesia. ( Ross, CA, 1987) |
| "Buspirone treatment also improved mitochondrial function and antioxidant activities." | 1.72 | The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson's Disease. ( Castorina, A; Thomas Broome, S, 2022) |
| " In this study we investigated the effect of chronic administration of buspirone and fluoxetine on cerebrospinal fluid (CSF) levels of inflammatory cytokines, TNF-α, IL-1β and IL-6 in 6-hydroxydopamine (6-OHDA)-lesioned rats." | 1.42 | Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats. ( Farajnia, S; Haddadi, R; Nayebi, AM; Sharifi, H, 2015) |
| "The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile." | 1.42 | Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. ( Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015) |
| "The treatment of Parkinson's disease with grafts of fetal ventral mesencephalic tissue has shown some success, but can result in graft-induced dyskinesias (GIDs)." | 1.36 | Graft-induced dyskinesias in Parkinson's disease: what is it all about? ( Barker, RA; Kuan, WL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas Broome, S | 1 |
| Castorina, A | 1 |
| Thomsen, M | 1 |
| Stoica, A | 1 |
| Christensen, KV | 1 |
| Fryland, T | 1 |
| Mikkelsen, JD | 1 |
| Hansen, JB | 1 |
| Schneider, RB | 1 |
| Auinger, P | 1 |
| Tarolli, CG | 1 |
| Iourinets, J | 1 |
| Gil-Díaz, MC | 1 |
| Richard, IH | 1 |
| Miyazaki, I | 1 |
| Asanuma, M | 1 |
| Murakami, S | 1 |
| Takeshima, M | 1 |
| Torigoe, N | 1 |
| Kitamura, Y | 1 |
| Miyoshi, K | 1 |
| Politis, M | 1 |
| Wu, K | 1 |
| Loane, C | 1 |
| Brooks, DJ | 1 |
| Kiferle, L | 1 |
| Turkheimer, FE | 1 |
| Bain, P | 1 |
| Molloy, S | 1 |
| Piccini, P | 1 |
| Sharifi, H | 1 |
| Nayebi, AM | 1 |
| Farajnia, S | 1 |
| Haddadi, R | 1 |
| Lindenbach, D | 1 |
| Palumbo, N | 1 |
| Ostock, CY | 1 |
| Vilceus, N | 1 |
| Conti, MM | 1 |
| Bishop, C | 1 |
| Beaulieu-Boire, I | 1 |
| Fasano, A | 1 |
| Levin, OS | 1 |
| Paquette, MA | 1 |
| Foley, K | 1 |
| Brudney, EG | 1 |
| Meshul, CK | 1 |
| Johnson, SW | 1 |
| Berger, SP | 1 |
| Barker, RA | 1 |
| Kuan, WL | 1 |
| Shin, E | 1 |
| Garcia, J | 1 |
| Winkler, C | 1 |
| Björklund, A | 1 |
| Carta, M | 1 |
| Bonifati, V | 1 |
| Fabrizio, E | 1 |
| Cipriani, R | 1 |
| Vanacore, N | 1 |
| Meco, G | 1 |
| Kleedorfer, B | 1 |
| Lees, AJ | 1 |
| Stern, GM | 1 |
| Ludwig, CL | 1 |
| Weinberger, DR | 1 |
| Bruno, G | 1 |
| Gillespie, M | 1 |
| Bakker, K | 1 |
| LeWitt, PA | 1 |
| Chase, TN | 1 |
| Ross, CA | 1 |
| Hammerstad, JP | 1 |
| Carter, J | 1 |
| Nutt, JG | 1 |
| Casten, GC | 1 |
| Shrotriya, RC | 1 |
| Alms, DR | 1 |
| Temple, D | 1 |
5 trials available for buspirone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.
Topics: Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Drug Tapering; Female; Humans; | 2020 |
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Buspirone; Case-Control Studies; Dopamine; Double-Blind Method; Dyskines | 2014 |
Buspirone in levodopa-induced dyskinesias.
Topics: Aged; Buspirone; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Midd | 1994 |
Buspirone, Parkinson's disease, and the locus ceruleus.
Topics: Anti-Anxiety Agents; Buspirone; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-B | 1986 |
Buspirone in the treatment of tardive dyskinesia.
Topics: Anti-Anxiety Agents; Buspirone; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans | 1987 |
12 other studies available for buspirone and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson's Disease.
Topics: Animals; Buspirone; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regula | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidin | 2022 |
Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Astrocytes; Brain; Buspirone; Ce | 2013 |
Effect of Chronic Administration of Buspirone and Fluoxetine on Inflammatory Cytokines in 6-Hydroxydopamine-lesioned Rats.
Topics: Animals; Buspirone; Cerebrospinal Fluid; Fluoxetine; Interleukin-1beta; Interleukin-6; Male; Oxidopa | 2015 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskin | 2015 |
Graft-induced dyskinesias fail to respond to 5HT1A agonist in the long-term.
Topics: Brain Tissue Transplantation; Buspirone; Dyskinesias; Female; Fetal Tissue Transplantation; Humans; | 2015 |
[The use of buspirone in clinical practice].
Topics: Anti-Anxiety Agents; Anxiety; Buspirone; Depression; Dyskinesia, Drug-Induced; Humans; Parkinson Dis | 2015 |
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyski | 2009 |
Graft-induced dyskinesias in Parkinson's disease: what is it all about?
Topics: Animals; Brain Tissue Transplantation; Buspirone; Dyskinesias; Fetal Tissue Transplantation; Humans; | 2010 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso | 2012 |
Buspirone in the treatment of levodopa induced dyskinesias.
Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hu | 1991 |
Buspirone in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Brain; Buspirone; Dopamine; Female; Humans; Male; Middle Aged; Pa | 1986 |